Compare SBFM & EDVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | EDVA |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.0M |
| IPO Year | 2008 | 2012 |
| Metric | SBFM | EDVA |
|---|---|---|
| Price | $2.75 | $0.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 534.9K | 472.2K |
| Earning Date | 11-24-2026 | 11-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,305,891.00 | $73,066.00 |
| Revenue This Year | $1.23 | $24,377.87 |
| Revenue Next Year | $22.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.13 | $0.13 |
| 52 Week High | $16.70 | $0.33 |
| Indicator | SBFM | EDVA |
|---|---|---|
| Relative Strength Index (RSI) | 66.32 | 43.06 |
| Support Level | $2.53 | $0.16 |
| Resistance Level | $3.25 | $0.19 |
| Average True Range (ATR) | 0.31 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 17.60 | 23.91 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.